[Cirrhotic cardiomyopathy]

Area of Science:

• Cardiology
• Hepatology
• Internal Medicine

Background:

• Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction in end-stage liver disease.
• It presents as systolic and/or diastolic dysfunction without prior heart conditions.
• Cardiac issues are often unapparent at rest but emerge during physiological stress.

Purpose of the Study:

• To review the characteristics and diagnostic challenges of cirrhotic cardiomyopathy.
• To highlight the importance of cardiac evaluation in patients with liver disease.

Main Methods:

• Diagnosis relies on echocardiography to detect subclinical cardiac dysfunction.
• Additional criteria include electrophysiological abnormalities (e.g., QT prolongation).
• Biomarkers (natriuretic peptides) and structural changes (left atrium enlargement) are also considered.

Main Results:

• CCM is characterized by impaired cardiac function, particularly under stress.
• Diagnosis requires a combination of imaging, electrophysiological, and biomarker assessments.
• No specific treatment exists for CCM.

Conclusions:

• Management focuses on supportive care and regular cardiac monitoring for high-risk individuals.
• Cardiac evaluation is crucial for transplant candidates and patients undergoing invasive procedures.
• Proactive management can mitigate risks associated with CCM in liver disease patients.